Improving medication adherence among patients with type 2 diabetes

Journal of Pharmacy Practice

Volumn 27, Issue 2, 2014, Pages 187-194

  Meece, Jerry ^a  

^a Plaza Pharmacy and Wellness Center ^*  (United States)

Author keywords

adherence; insulin; persistence; pharmacists; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ARTICLE; DIABETES EDUCATION; DIABETIC PATIENT; EVENING DOSAGE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; MOTIVATIONAL INTERVIEWING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACIST ATTITUDE; SYSTEMATIC REVIEW; COOPERATION; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; PHARMACIST; PROFESSIONAL STANDARD; PSYCHOLOGY; STANDARDS;

COOPERATIVE BEHAVIOR; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; PHARMACISTS; PROFESSIONAL ROLE;

EID: 84898943703     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013513803     Document Type: Article

References (48)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed March 22, 2011.
2. Centers for Disease Control and Prevention. Diabetes: successes and opportunities for population-based prevention and control. At a glance 2011. http://www.cdc.gov/chronicdisease/resources/publications/AAG/ddt.htm. Accessed December 17, 2012.
3. Perera PN, Guy MC, Sweaney AM, et al. Evaluation of prescriber responses to pharmacist recommendations communicated by fax in a medication therapy management program (MTMP). J Manag Care Pharm. 2011 ; 17 (5). 345-354
4. Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012 ; 29 (5). 682-689
5. Standards of medical care in diabetes - 2013. Diabetes Care. 2013 ; 36 (suppl 1). S11 - S66
6. Butler AE, Janson J, Bonner-Weir S, et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003 ; 52 (1). 102-110
7. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004 ; 88 (4). 787-835
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 ; 321 (7258). 405-412
9. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010 ; 376 (9739). 419-430
10. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 ; 28 (2). 103-117
11. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352 (9131). 837-853
12. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 ; 352 (9131). 854-865
13. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 ; 359 (15). 1577-1589
14. Joslin Diabetes Center and Joslin Clinic. Clinical guideline for pharmacological management of type 2 diabetes, 1/09/2009 (updated 11/2010). http://www.joslin.org/bin-from-cms/Pharma-guideline-11.-10.pdf. Accessed March 10, 2011.
15. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 ; 15 (6). 540-559
16. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2012 ; 35 (6). 1364-1379
17. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization ; 2003 :
18. MacLaughlin EJ, Raehl CL, Treadway AK, et al. Assessing medication adherence in the elderly: which tools to use in clinical practice?. Drugs Aging. 2005 ; 22 (3). 231-255
19. Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004 ; 38 (9). 1357-1362
20. Kogut SJ, Andrade SE, Willey C, et al. Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation). Pharmacoepidemiol Drug Saf. 2004 ; 13 (9). 591-598
21. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011 ; 33 (1). 74-109
22. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 2005 ; 27 (7). 1064-1073
23. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002 ; 19 (4). 279-284
24. Rajaopalan R, Joyce A, Smith D, et al. Medication compliance in type 2 diabetes patients: retrospective data analysis [abstract]. Value Health. 2003 ; 6 (3). 328
25. Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diabetes Educ. 2008 ; 34 (4). 692-697
26. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008 ; 11 (1). 44-47
27. Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008 ; 62 (1). 76-87
28. Zhang Q, Zhao C, Davies MJ, et al. Compliance and persistence with concomitant statin and oral antihyperglycemic therapy. Am J Manag Care. 2011 ; 17 (11). 746-752
29. Armor BL, Britton ML, Dennis VC, et al. A review of pharmacist contributions to diabetes care in the United States. J Pharm Practice. 2010 ; 23 (3). 250-264
30. Giberson S, Yoder S, Lee MP Improving patient and health system outcomes through advanced pharmacy practice. A report to the U.S. Surgeon General 2011. Rockville, MD: Office of the Chief Pharmacist. U.S. Public Health Service ; 2011 :
31. Benjamin R U.S. Surgeon General support letter for Giberson 2011. Rockville, MD: Office of the Surgeon General ; 2011 :
32. Grossman S. Management of type 2 diabetes mellitus in the elderly: role of the pharmacist in a multidisciplinary health care team. J Multidiscip Healthc. 2011 ; 4: 149-154
33. Fera T, Bluml BM, Ellis WM, et al. The diabetes ten city challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program. J Am Pharm Assoc (2003). 2008 ; 48 (2). 181-190
34. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008 ; 28 (4). 421-436
35. Cranor CW, Bunting BA, Christensen DB. The Asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003 ; 43 (2). 173-184
36. Jameson JP, Baty PJ. Pharmacist collaborative management of poorly controlled diabetes mellitus: a randomized controlled trial. Am J Manag Care. 2010 ; 16 (4). 250-255
37. Machado M, Bajcar J, Guzzo GC, et al. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007 ; 41 (10). 1569-1582
38. Brennan TA, Dollear TJ, Hu M, et al. An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients. Health Aff (Millwood). 2012 ; 31 (1). 120-129
39. Dunn JD. Diabetes pharmacy management: balancing safety, cost, and outcomes. Am J Manag Care. 2010 ; 16 (7 suppl). S201 - S206
40. Funnell MM, Brown TL, Childs BP, et al. National standards for diabetes self-management education. Diabetes Care. 2012 ; 35 (suppl 1). S101 - S108
41. Heisler M, Vijan S, Makki F, et al. Diabetes control with reciprocal peer support versus nurse care management: a randomized trial. Ann Intern Med. 2010 ; 153 (8). 507-515
42. American Association of Diabetes Educators. AADE7TM self-care diabetes. http://www.diabeteseducator.org/. Accessed August 15, 2012.
43. Meece J. Pharmacoeconomic advantages of insulin analogs. U S Pharmacist. 2006 ; 31 (12). HS42 - HS50
44. Fisher WA, Cornman DH, Kohut T, et al. What primary care providers can do to address barriers to self-monitoring of blood glucose. Clin Diabetes. 2013 ; 31 (1). 34-42
45. Mayberry LS, Osborn CY. Family support, medication adherence, and glycemic control among adults with type 2 diabetes. Diabetes Care. 2012 ; 35 (6). 1239-1245
46. Walker EA, Shmukler C, Ullman R, et al. Results of a successful telephonic intervention to improve diabetes control in urban adults: a randomized trial. Diabetes Care. 2011 ; 34 (1). 2-7
47. Armor BL. Part D resources for pharmacists. J Pharm Practice. 2010 ; 23 (2). 144-145
48. Sisson E, Kuhn C. Pharmacist roles in the management of patients with type 2 diabetes. J Am Pharm Assoc (2003). 2009 ; 49 (suppl 1). S41 - S45